|
|
Article: Molecular Partners Gets $15M For Multiuse DARPin Proteins.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
BioWorld International Correspondent
Molecular Partners AG raised CHF18.5 million (US$15.3 million) in a heavily oversubscribed Series A round to progress its preclinical portfolio of Designed Ankyrin Repeat Proteins (DARPins), which have multiple therapeutic and diagnostic applications.
Since there were "dozens" of potential investors, closing the round took longer than originally anticipated, Molecular Partners CEO Christian Zahnd said. "We had quite a number of term sheets on the table."
The recent spate of acquisition activity in the field sparked the interest, Zahnd said, referring to the acquisitions of Domantis Ltd. and Avidia Inc. by ...